(IN BRIEF) The European Investment Bank (EIB) and Romania’s leading pharmaceutical manufacturer, Antibiotice, have partnered to support the production of medicines in Romania. Through a €25 million loan agreement, the EIB will finance the construction of a modern production, packaging, … Read the full press release
Posted in Banks, Business, Construction, Economy, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Luxembourg, Management, News, Pharma & Biotech, Romania, Technology
Tagged Antibiotice, European Investment Bank, Healthcare, Ioan Nani, Medicine Production, Paolo Gentiloni, partnership, Romania, sustainability, Teresa Czerwinska
(IN BRIEF) Novo Nordisk has unveiled plans to invest more than 42 billion Danish kroner starting in 2023 to expand its existing manufacturing facilities in Kalundborg, Denmark. This significant investment coincides with the company’s 100th anniversary and underscores Novo Nordisk’s … Read the full press release
(IN BRIEF) Kuehne+Nagel’s North American Road Logistics team received an urgent request from a pharmaceutical customer to deliver 150 pallets of flu vaccines to over 40 Veterans Affairs (VA) hospitals across the U.S. within ten days. The team quickly organized … Read the full press release
(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab), in combination with transarterial chemoembolisation (TACE) and bevacizumab, significantly improves progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) eligible … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, bevacizumab, Dr. Riccardo Lencioni, EMERALD-1, HCC, Imfinzi, Imfinzi Combination Therapy, Liver Cancer Treatment, Phase III Trial, Susan Galbraith, TACE
(IN BRIEF) AstraZeneca and Eccogene have signed an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) designed for the treatment of obesity, type-2 diabetes, and other cardiometabolic conditions. Initial results from the Phase … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Cardiometabolic Conditions, ECC5004, Eccogene, Exclusive License, Jingye Zhou, Obesity, Oral GLP-1RA, partnership, Sharon Barr, sustainability, type 2 diabetes
(IN BRIEF) Roche, a leading healthcare company, has announced that its Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is designed … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Elecsys NfL Test, FDA, Matt Sause, multiple sclerosis, Roche
(IN BRIEF) Health Canada has granted authorization for the probiotic strain Lactobacillus acidophilus DDS-1® to make health claims related to the gut-brain axis. The strain is now approved to help alleviate perceived stress, improve irritable bowel syndrome (IBS)-related quality of … Read the full press release
Posted in Denmark, Food & Beverage, Healthcare, Pharma & Biotech, Science
Tagged Brain, Chr. Hansen, DDS-1®, digestive issues, gut, gut-brain axis, Health Canada, IBS, irritable bowel syndrome, L. acidophilus, Linda Neckmar, mental well-being, microbiome, Natural Health Product, Niklas Larsson PhD, NPH license, probiotic strain, stress
(IN BRIEF) A recent study led by the Technical University of Munich (TUM) reveals that late-stage Parkinson’s disease patients may benefit from changes in treatment, even after invasive therapies have been attempted. The study analyzed data from 22 German Parkinson’s … Read the full press release
(IN BRIEF) The European Society of Cardiology (ESC) has issued a statement regarding the proposed Reform of the EU Pharmaceutical Legislation by the European Commission, currently in negotiation in the European Parliament and the Council. While the ESC supports the … Read the full press release
(IN BRIEF) Kuehne+Nagel, a global logistics company, has achieved its third consecutive IATA CEIV Pharma certification for its entire air logistics healthcare network. This milestone makes Kuehne+Nagel the first logistics company with over 100 CEIV Pharma-certified stations. IATA’s CEIV Pharma … Read the full press release
(IN BRIEF) BASF, a global chemical company, has entered into an innovation partnership with 3Helix Inc., a U.S.-based technology start-up, to leverage 3Helix’s proprietary CHP (Collagen Hybrid Peptides) technology. This collaboration involves an equity investment and licensing agreement, granting BASF … Read the full press release
Posted in Apparel, Fashion & Beauty, Business, Chemicals, Environment, Financial, Germany, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged 3Helix, Anti-Aging Technology, BASF, CHP technology, Dr. Marina Safont Sempere, INNOVATION, Mike Kirkness, partnership, sustainability
(IN BRIEF) Medidata, a subsidiary of Dassault Systèmes, is hosting NEXT New York 2023, a major clinical research conference in New York City from November 7-8. This event will bring together over 700 leaders in the life sciences industry to … Read the full press release
(IN BRIEF) Finnish biotechnology start-up Origin by Ocean has teamed up with AFRY, a global engineering and advisory firm, to work on an ambitious project aimed at establishing an industrial-scale biorefinery in Finland. The collaborative effort focuses on refining seaweed … Read the full press release
Posted in Business, Environment, Financial, Finland, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged AFRY, Finland, innovative, Mari Granström, Origin by Ocean, partnership, Seaweed Biorefinery, sustainability, Tuukka Sormunen
(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, André Choulika, AstraZeneca, Cellectis, gene therapy, immunology, Marc Dunoyer, oncology, partnership, rare diseases, sustainability
(IN BRIEF) Researchers at the University of Leicester have developed a groundbreaking treatment for severe asthma using the monoclonal antibody tezepelumab. This monthly injection targets thymic stromal lymphopoietin (TSLP), a substance associated with inflammation in the airways of severe asthma … Read the full press release
(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged ADC, antibody-drug conjugate, ATM, ATR, Cancer, CEACAM5-targeting ADC, Claudin-18.2, Danny Bar-Zohar, DDR cascade, DNA-PK, Frank Jiang, Hengrui, HRS-1167, inhibitor, Jiangsu Hengrui Pharmaceuticals Co. Ltd., M9140, Merck, metastatic colorectal cancer, oncology, PARP, PARP1, poly (ADP-ribose) polymerase 1, SHR-A1904
(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release
(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annaliesa Anderson, BioNTech, Combination Vaccine, Comirnaty, COVID-19, influenza, influenza A, influenza B, mRNA, partnership, Pfizer, Prof. Ugur Sahin, respiratory diseases, SARS-CoV-2 strains, sustainability, wellness
(IN BRIEF) AstraZeneca’s Supplemental Biologics License Application (sBLA) seeking approval for a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray flu vaccine, has been accepted for review by the US Food and Drug Administration (FDA). If approved, … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?